This article is more than 5 years old. Information may no longer be current.

Corindus launches CorPath One Stent Program for cardiac cath labs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

With the launch of the CorPath One Stent Program, Corindus Vascular Robotics will offer a $1,000 credit to hospitals that use two or more stents per lesion in coronary angioplasties performed with the CorPath robotic-assisted angiography system.

The CorPath Vascular Robotic System is the first FDA-approved procedure to allow controlled placement of coronary guidewires and stent/balloon catheters from an interventional, lead-lined cockpit.

The goal is to reduce longitudinal geographic miss, which is associated with increased target vessel revascularization, Tal Wenderow, co-founder and executive vice president of business strategy and marketing at Corindus Vascular Robotics, told Cardiology Today. Previous research demonstrated that “when you place the right stent in the right place, patients have a 2.3 times lower rate of TVR” at 12 months compared with longitudinal geographic miss cases, he said. Therefore, the system was also designed to “help the physician measure the anatomy and optimize the appropriate stent length,” he said.

The system offers precise stent placement that allows physicians “to manipulate the interventional device in 1-mm increments with precise 30° rotational movements,” Wenderow said. “The ability to accurately place the stent allows physicians to optimize their PCI procedures and provide better clinical outcomes for their patients.”

In the PRECISE pivotal trial, which was the basis for the system’s FDA approval, procedures using the CorPath System averaged 1.1 stents per lesion, compared with a historical rate of 1.21 stents per lesion for conventional stent-placement procedures, he said.

A prospective registry study to confirm the findings of PRECISE is underway. The goal of the CorPath One Stent Program is to give physicians confidence in using the system until those data become available, Wenderow told Cardiology Today. “We believe that this program makes sense both financially to the hospitals and clinically to the patients.”

For more information:

Costa MA. Am J Cardiol. 2008;101:1704-1711.

Weisz G. J Am Coll Cardiol. 2013;61:1596-1600.

Disclosure: Wenderow is an employee of Corindus Vascular Robotics, which he co-founded.